

West Yorkshire & Harrogate (WY&H) Joint Committee of Clinical Commissioning Groups Summary of key decisions - Meeting in public, Tuesday 5 November 2019

Knee policies

As part of the Elective Care/Standardisation of Commissioning Policies Programme, the Committee considered WY&H-wide policies for knee replacement surgery and key-hole surgery. Both policies require conservative management options to be tried and to have shown no benefit before referral for orthopaedic assessment. They also require lifestyle factors like BMI and smoking status to be assessed, as they may influence long term health outcomes. Shared decision-making between the patient and clinician will be important to ensure that patients understand the risks and benefits of the procedures. More information is available here: A single approach to knee surgery for West Yorkshire and Harrogate

The Committee noted the need for each place across WY&H to put in place robust plans to implement the policy over the next 12 months. This would include workforce development and working closely with musculoskeletal services and other providers to ensure that sufficient capacity was available and that a 'whole system' approach was taken to implementation.

The Joint Committee: Agreed to adopt the knee policies across WY&H.

Hydroxychloroquine and chloroquine retinopathy monitoring – pathway and policy

The Committee considered a WY&H-wide pathway and policy for monitoring the side effects of hydroxychloroquine and chloroquine – drugs used to treat rheumatoid arthritis, skin conditions and other conditions that involve inflammation. Some people who take hydroxychloroquine or chloroquine for more than five years, or in high doses, are at increased risk of damage to their retina. In 2018, the Royal College of Ophthalmologists had issued new guidance about monitoring. The Committee heard that no hydroxychloroquine retinopathy monitoring services are currently commissioned in WY&H.

The Committee noted the financial and capacity challenges involved in implementing the policy. The Elective Care/Standardisation of Commissioning Policies Programme is working with partner organisations across eye care services to consider the various options for delivering the service following agreement of the new pathway and policy.

The Joint Committee: Agreed to adopt the Hydroxychloroquine and Chloroquine Retinopathy Monitoring Pathway and Policy across WY&H, with a three year timeframe for full implementation.

Joint Committee governance

The Committee noted that the Memorandum of Understanding (MoU) for Collaborative Commissioning was due to expire on 31st March 2020. The Committee considered a range of proposals to further strengthen collaborative working. These included developing the Committee's work plan to reflect the progress that had been made and take into account new priorities. A new approach to monitoring implementation of the Committee's decisions was also discussed. The Committee supported work to develop the proposals, including further discussion within each CCG. The revised proposals would then be brought back to the Joint Committee development session in December.

The Joint Committee: Agreed that following further discussion at the development session in December, the proposals be presented to the individual CCGs for consideration.

The Joint Committee has delegated powers from the WY&H CCGs to make collective decisions on specific, agreed WY&H work programmes. It can also make recommendations to the CCGs. The Committee supports the wider HCP, but does not represent all of the partners. Further information is available on the Joint Committee web pages: https://wyh-jointcommitteeccgs.co.uk/ or from Stephen Gregg, stephen.gregg@wakefieldccg.nhs.uk.